Manufacturers return some drugs to market but shortages persist Read more: Manufacturers return some drugs to market but shortages persist - FiercePharma Manufacturing http://www.fiercepharmamanufacturing.com/story/manufacturers-return-some-drugs-market-shortages-persist/2012-11-20#ixzz2CrnbvlgW Subscribe: http://www.fiercepharmamanufacturing.com/signup?sourceform=Viral-Tynt-FiercePharma Manufacturing-FiercePharma Manufacturing

November 20, 2012 | By Eric Palmer

There has been some progress on the drug shortages front in the last few weeks with a couple of drugmakers saying manufacturing improvements have allowed them to again meet demand for two critical drugs. But as The New York Times points out, even with new drug shortages popping up at half the numbers of a year ago, there are still dozens of drugs in short supply, forcing some patients to go without essential meds and forcing healthcare providers to make some tough choices.

Just last week, Genzyme said that a new plant was now producing all of the supply needed for its thyroid cancer treatment, Thyrogen. And Hospira ($HSP), which has been at the heart of a number of drug shortages as it works through improvements to its manufacturing plants, said it expects to soon have sufficient supplies to re-enter the market with propofol. The anesthetic is one of the drugs hospitals had turned to the large-sale compounder, Ameridose, for because it was hard to come by. Now Ameridose has closed because of FDA issues, a move that may lead to a number of shortages.

Read more: Manufacturers return some drugs to market but shortages persist - FiercePharma Manufacturing http://www.fiercepharmamanufacturing.com/story/manufacturers-return-some-drugs-market-shortages-persist/2012-11-20#ixzz2CrnkbSkI
Subscribe: http://www.fiercepharmamanufacturing.com/signup?sourceform=Viral-Tynt-FiercePharma Manufacturing-FiercePharma Manufacturing